Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Journal of Autoimmunity|November 1, 2005
Type 1 diabetes genes and pathways shared by humans and NOD miceLinda S Wicker, Jan Clark, Heather I Fraser, et al.
Transplantation|April 15, 1996
Evaluation of the flow cytometric crossmatch. Preliminary results of a multicenter studyA W Harmer, S Garner, A E Bell, et al.
Clinical Pharmacology and Therapeutics|September 15, 2016
Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-MakingS Schneeweiss, H-G Eichler, A Garcia-Altes, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 30, 2009
Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammationCynthia D Sommers, Janice M Thompson, Julia A Guzova, et al.
Novartis Foundation Symposium|July 8, 2005
Natural genetic variants influencing type 1 diabetes in humans and in the NOD mouseLinda S Wicker, Carolyn L Moule, Heather Fraser, et al.
Clinical Pharmacology and Therapeutics|February 17, 2012
Adaptive licensing: taking the next step in the evolution of drug approvalH-G Eichler, K Oye, L G Baird, et al.
Nature Genetics|February 6, 2007
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunityJun Yamanouchi, Dan Rainbow, Pau Serra, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patientsH-G Eichler, L G Baird, R Barker, et al.
Pageof 12